These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

666 related items for PubMed ID: 26034358

  • 21. Aggressive use of ribavirin and prolonged course of peginterferon to improve the rate of viral response in liver transplant patients with recurrent hepatitis C viral infection.
    Singhal A, Jain AB, Burke M, Black M.
    Exp Clin Transplant; 2010 Sep; 8(3):214-9. PubMed ID: 20716039
    [Abstract] [Full Text] [Related]

  • 22. Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation.
    Kawaoka T, Takahashi S, Takaki S, Hiramatsu A, Waki K, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Aikata H, Ochi H, Onoe T, Tashiro H, Ohdan H, Chayama K.
    J Gastroenterol Hepatol; 2012 Sep; 27(9):1467-72. PubMed ID: 22432893
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Treatment of recurrent HCV infection following liver transplantation: results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFNα-2a plus ribavirin.
    Calmus Y, Duvoux C, Pageaux G, Wolf P, Rostaing L, Vanlemmens C, Botta-Fridlund D, Dharancy S, Gugenheim J, Durand F, Néau-Cransac M, Boillot O, Chazouillères O, Samelson L, Boudjema K, Samuel D.
    J Hepatol; 2012 Sep; 57(3):564-71. PubMed ID: 22613001
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
    Zimmermann T, Böcher WO, Biesterfeld S, Zimmermann A, Kanzler S, Greif-Higer G, Barreiros AP, Sprinzl MF, Wörns MA, Lohse AW, Mönch C, Otto G, Galle PR, Schuchmann M.
    Transpl Int; 2007 Jul; 20(7):583-90. PubMed ID: 17433090
    [Abstract] [Full Text] [Related]

  • 29. Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases.
    Iacob S, Gheorghe L, Hrehoret D, Becheanu G, Herlea V, Popescu I.
    J Gastrointestin Liver Dis; 2008 Jun; 17(2):165-72. PubMed ID: 18568137
    [Abstract] [Full Text] [Related]

  • 30. Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes.
    Torres-Cornejo A, Ruiz-Valderas R, Jimenez-Jimenez L, Abad-Molina C, Gutierrez-Valencia A, Viciana P, Lopez-Cortes LF.
    J Viral Hepat; 2014 Mar; 21(3):178-88. PubMed ID: 24438679
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.
    Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, Stauber R, Bischof M, Bauer B, Datz C, Löschenberger K, Formann E, Staufer K, Steindl-Munda P, Austrian Hepatitis Study Group.
    Gastroenterology; 2008 Aug; 135(2):451-8. PubMed ID: 18503773
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
    Ascione A, De Luca M, Tartaglione MT, Lampasi F, Di Costanzo GG, Lanza AG, Picciotto FP, Marino-Marsilia G, Fontanella L, Leandro G.
    Gastroenterology; 2010 Jan; 138(1):116-22. PubMed ID: 19852964
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Efficacy and safety of low accelerating dose regimen of interferon/ribavirin antiviral therapy in patients with hepatitis C virus recurrence after liver transplantation.
    Su H, Liu Z, Sun Y, Li H, Zhou S, Zhou X, Gao Y, Tang R, Zhang D, Zhang M.
    Ann Transplant; 2015 May 11; 20():263-8. PubMed ID: 25975740
    [Abstract] [Full Text] [Related]

  • 38. Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study.
    Verna EC, Saxena V, Burton JR, O'Leary JG, Dodge JL, Stravitz RT, Levitsky J, Trotter JF, Everson GT, Brown RS, Terrault NA, CRUSH-C Consortium.
    Transplantation; 2015 Aug 11; 99(8):1644-51. PubMed ID: 25715116
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Treatment of genotype 4 hepatitis C recurring after liver transplantation using a combination of pegylated interferon alfa-2a and ribavirin.
    Al-Hamoudi W, Mohamed H, Abaalkhail F, Kamel Y, Al-Masri N, Allam N, Alqahtani S, Al-Sofayan M, Khalaf H, Al-Sebayel M, Al-Jedai A, Abdo A.
    Dig Dis Sci; 2011 Jun 11; 56(6):1848-52. PubMed ID: 21221800
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.